Gennady Landa, MD, is vice chair, clinical integration of ophthalmology, Mount Sinai Health System; director of retina service, NYEEI; and associate professor of ophthalmology, vitreoretinal surgeon ...

Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Afqlir (aflibercept) is a 2 mg vial kit and pre-filled syringe for intravitreal injection. The European Commission (EC) granted marketing authorization for Afqlir (aflibercept), which is a 2 mg vial ...

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection. The ideal syringe for administering intravitreal injections does not exist ...

The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy. OcuTerra announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) ...

Recapping a recent conversation led by Dilsher S. Dhoot, MD. In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Eyestem received approval from India’s Central Drugs Standards Control Organisation (CDSCO) to commence human trials for Eyecyte RPE, a potential treatment for geographic atrophy arising from dry ...

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease. Belite Bio, Inc has dosed the first patient at the Tokyo Medical Center in the ...